During the last session, Autolus Therapeutics plc (NASDAQ:AUTL)’s traded shares were 0.56 million, with the beta value of the company hitting 1.58. At the end of the trading day, the stock’s price was $2.37, reflecting an intraday loss of -1.25% or -$0.03. The 52-week high for the AUTL share is $8.23, that puts it down -247.26 from that peak though still a striking 7.17% gain since the share price plummeted to a 52-week low of $2.20. The company’s market capitalization is $247.36M, and the average intraday trading volume over the past 10 days was 0.28 million shares, and the average trade volume was 285.47K shares over the past three months.
Autolus Therapeutics plc (AUTL) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. AUTL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.51.
Autolus Therapeutics plc (NASDAQ:AUTL) trade information
Autolus Therapeutics plc (AUTL) registered a -1.25% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.25% in intraday trading to $2.37 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -16.55%, and it has moved by -42.48% in 30 days. Based on these gigs, the overall price performance for the year is -61.59%. The short interest in Autolus Therapeutics plc (NASDAQ:AUTL) is 2.32 million shares and it means that shorts have 3.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $13.50, which implies an increase of 82.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $20.00 respectively. As a result, AUTL is trading at a discount of -743.88% off the target high and -195.36% off the low.
Autolus Therapeutics plc (AUTL) estimates and forecasts
Statistics show that Autolus Therapeutics plc has outperformed its competitors in share price, compared to the industry in which it operates. Autolus Therapeutics plc (AUTL) shares have gone down -64.89% during the last six months, with a year-to-date growth rate more than the industry average at 9.64% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 29.20% this quarter and then jump 38.60% in the quarter after that. In the rating firms’ projections, revenue will increase 19.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $250k as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $250k by the end of Dec 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $300k and $404k respectively. In this case, analysts expect current quarter sales to shrink by -16.70% and then drop by -38.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -31.10%. While earnings are projected to return 28.50% in 2022.
Autolus Therapeutics plc is due to release its next quarterly earnings between March 02 and March 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Autolus Therapeutics plc (NASDAQ:AUTL)’s Major holders
Autolus Therapeutics plc insiders own 25.23% of total outstanding shares while institutional holders control 59.60%, with the float percentage being 79.71%. Frazier Management LLC is the largest shareholder of the company, while 73 institutions own stock in it. As of Sep 29, 2021, the company held over 3.53 million shares (or 4.84% of all shares), a total value of $23.13 million in shares.
The next largest institutional holding, with 2.96 million shares, is of Capital World Investors’s that is approximately 4.05% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $19.36 million.
Also, the Mutual Funds coming in first place with the largest holdings of Autolus Therapeutics plc (AUTL) shares are Smallcap World Fund and Fidelity Advisor Biotechnology Fund. Data provided on Sep 29, 2021 indicates that Smallcap World Fund owns about 2.96 million shares. This amounts to just over 4.05 percent of the company’s overall shares, with a $19.36 million market value. The same data shows that the other fund manager holds slightly less at 1.0 million, or about 1.37% of the stock, which is worth about $5.56 million.